PRECIGEN, INC.
No SEC Form 4 filings for $PGEN in the last 30 days.
See all $PGEN insider activity →Patient Capital Management's Q3 2026 investor letter highlights Precigen (PGEN) as a top holding. The biopharmaceutical company's stock has gained ~86.84% YTD, driven by the successful launch of its drug Papzimeous. The company's market cap is $2.8 billion, and it recently received FDA platform designation for its Adenoverse technology.
On September 30, 2026, biotech stocks PGEN, EXEL, TWST, HNGE, and PBYI hit 52-week highs. PGEN rose 6% to $9.98, EXEL reached $61.14, TWST climbed 3% to $197.19, HNGE hit $98.41, and PBYI touched $10.10. Key catalysts included clinical trial results, FDA designations, and revenue growth.
Precigen (PGEN) received FDA Platform Technology Designation for AdenoVerse, the technology behind PAPZIMEOS. The designation may reduce development costs for future drugs, including PRGN-2009, an investigational cancer treatment. Management expects benefits but has not quantified cost savings or timelines. The FDA's draft guidance outlines potential benefits, but Precigen must provide supporting evidence for reuse of prior data. Hedge fund sentiment showed a slight decrease in holdings.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PGEN (PRECIGEN, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PGEN coverage spans market movers, insider activity and regulation.
FDA platform designation plus a successful first-drug launch are framed as de-risking the pipeline and supporting upside expectations ahead of upcoming trial readouts.
Positive clinical and regulatory news likely fuels further upside.
The designation may enable cost and timeline efficiencies for Precigen's pipeline, creating upside potential.
Coverage initiation could attract buying pressure for the biotech.
Positive regulatory milestone likely to accelerate development and boost valuation.
AlphAI scores every news story that mentions PGEN with an AI model for sentiment and relevance, and aggregates insider trades from PRECIGEN, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Patient Capital Management's Q3 2026 investor letter highlights Precigen (PGEN) as a top holding. The biopharmaceutical company's stock has gained ~86.84% YTD, driven by the successful launch of its drug Papzimeous. The company's market cap is $2.8 billion, and it recently received FDA platform designation for its Adenoverse technology.
5 min readOn September 30, 2026, biotech stocks PGEN, EXEL, TWST, HNGE, and PBYI hit 52-week highs. PGEN rose 6% to $9.98, EXEL reached $61.14, TWST climbed 3% to $197.19, HNGE hit $98.41, and PBYI touched $10.10. Key catalysts included clinical trial results, FDA designations, and revenue growth.
2 min readPrecigen (PGEN) received FDA Platform Technology Designation for AdenoVerse, the technology behind PAPZIMEOS. The designation may reduce development costs for future drugs, including PRGN-2009, an investigational cancer treatment. Management expects benefits but has not quantified cost savings or timelines. The FDA's draft guidance outlines potential benefits, but Precigen must provide supporting evidence for reuse of prior data. Hedge fund sentiment showed a slight decrease in holdings.
3 min readMizuho initiated coverage on Tower Semiconductor (TSEM) with an Outperform rating and $300 price target. Other initiations include Precigen (PGEN) with a Buy rating and $12 target, Seaport Therapeutics (SPTX) with a Strong Buy rating and $46 target, PDF Solutions (PDFS) with a Buy rating and $60 target, and CF Industries (CF) with an Outperform rating and $162 target.
2 min readPrecigen, Inc. (PGEN) announced that the FDA granted platform technology designation to its AdenoVerse® immunotherapeutic platform, used in its commercial product PAPZIMEOS®. This designation may accelerate the development of future therapies by leveraging existing data and reducing duplicative work. The company's CEO highlighted the potential benefits for its clinical portfolio, including PRGN-2009 for HPV-associated cancers.
2 min readKINDLER JEFFREY B sold 185,000 shares of PRECIGEN, INC. (PGEN) at $7.44 ($1.38M total) on 2026-08-26.
1 min readAGEE NANCY H purchased 3,411 shares of PRECIGEN, INC. (PGEN) at $7.23 on 2026-08-21.
1 min readTennant Phil (Chief Commercial Officer) sold 79,166 shares of PRECIGEN, INC. (PGEN) at $7.50 ($0.59M total) on 2026-08-25 under a Rule 10b5-1 trading plan.
1 min readModerna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.
3 min readPrecigen (PGEN) reported Q2 2026 PAPZIMEOS net revenue of $53.1 million, up 145.8% sequentially from $21.6 million, and first quarterly net income of $20.1 million, or $0.05 per diluted share. Gross margin was 95% but management expects normalization to high 80% to low 90%. Cash and investments were $38.7 million at June 30, 2026.
6 min read
